Cacciuttolo was MedImmune, Medarex Technical Operations vice president, and was recently president and CEO of PERCIVIA.
The company also appointed Ben Machielse and Robert Gailus to the Board of Directors and established its headquarters in Cambridge, Massachusetts.
Machielse was recently executive vice president of Operations at MedImmune.
Ben played a role in all aspects of the manufacture of Synagis and FluMist (Influenza Virus Vaccine Live, Intranasal), developing and launching the H1N1 vaccine and managing relations with the government.
Gailus was a financial advisor to Ogden-CAP Associates and now joins the board as a venture investor.
Tetragenetics president and CEO Marco Cacciuttolo said the Tetragenetics technology brings potential to accelerate vaccine discovery and reduce manufacturing costs.